Table 1.
Clinical and histopathological parameters available for breast and lung cancer tumor cohorts
| BRCA | No. | % | Lung | No. | % |
|---|---|---|---|---|---|
| Tumor stage | Tumor stage | ||||
| T1 | 14 | 32.6 | T1 | 3 | 5.2 |
| T2 | 20 | 46.5 | T2 | 44 | 75.9 |
| T3 | 3 | 7.0 | T3 | 8 | 13.8 |
| T4 | 2 | 4.7 | T4 | 3 | 5.2 |
| TX | 4 | 9.3 | |||
| Nodal status | Nodal status | ||||
| Negative | 16 | 37.2 | Negative | 27 | 46.6 |
| Positive | 20 | 46.5 | Positive | 31 | 53.4 |
| NX | 7 | 16.3 | |||
| Gender | Gender | ||||
| Male | 0 | 0 | Male | 44 | 75.9 |
| Female | 43 | 100 | Female | 14 | 24.4 |
| ER status | Differentiation | ||||
| Negative | 10 | 23.3 | Good | 19 | 32.8 |
| Positive | 25 | 58.1 | Moderate | 31 | 53.4 |
| Equivocal | 1 | 2.3 | Poor | 7 | 12.1 |
| No data | 7 | 16.3 | |||
| PR status | Histology | ||||
| Negative | 9 | 20.9 | SqCCL | 32 | 55.2 |
| Positive | 25 | 58.1 | AdenoCa | 24 | 41.8 |
| Equivocal | 2 | 4.6 | Anaplastic Ca | 1 | 1.7 |
| No data | 7 | 16.3 | |||
| HER2+ | NSCLC | 1 | 1.7 | ||
| Negative | 28 | 65.1 | Follow‐up | ||
| Positive | 8 | 18.6 | Alive | 4 | 6.9 |
| No data | 7 | 16.3 | Dead | 52 | 89.7 |
| Triple negative breast cancer | 4 | 9.3 | Age, mean age (range) | 67.1 | 48.5–87.5 |